The flow cytometry market boasts diverse products catering to various analytical needs, including instruments, reagents, software, accessories, and services. Technologies include cell-based flow cytometry, precise cellular analysis, and bead-based flow cytometry, known for multiplexed assays. Instruments ensure accurate data acquisition, while reagents facilitate sample preparation. Software aids in data analysis and accessories enhance instrument functionality. Services encompass calibration and maintenance. This comprehensive range empowers researchers with versatile tools, driving cellular analysis and diagnostics advancements.
Access Full Report @ https://www.databridgemarketresearch.com/ar/reports/asia-pacific-flow-cytometry-market
Data Bridge Market Research analyses that the Asia-Pacific Flow Cytometry Market is growing with a CAGR of 10.7% in the forecast period of 2023 to 2030 and is expected to reach USD 2,395.04 million by 2030 from USD 1,068.66 million in 2022. The driver of biomedical research advancements in the flow cytometry market highlights the crucial role of sophisticated flow cytometry technologies in meeting the evolving demands of ongoing biomedical research. The need for precise and advanced analytical tools drives the market's growth, supporting breakthroughs in medical science.
Key Findings of the Study
Growing clinical applications are expected to drive the market's growth rate
The driver, growing clinical applications, signifies the pivotal role of flow cytometry in expanding realms such as immunology and hematology. As clinical applications broaden, the demand for flow cytometry technologies surges. These tools enable precise cellular analysis, supporting advancements in understanding diseases and facilitating tailored treatments. The market's expansion is propelled by its indispensable role in clinical research, contributing to enhanced diagnostic capabilities and paving the way for personalized healthcare solutions.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Flow Cytometry Instruments, Reagents and Consumables, Software, Accessories, and Services), Technology (Cell-Based Flow Cytometry and Bead-Based Flow Cytometry), Application (Research Applications, Clinical Applications, and Industrial Applications), End User (Academic and Research Institutes, Hospitals, Pharmaceutical and Biotechnology Companies, Clinical Testing Laboratories, Blood Bank, and Others), Distribution Channel (Direct Tenders, and Retail Sales)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), Coherent Corp. (U.S.), Beckman Coulter, Inc. (A subsidiary of Danaher Corporation) (U.S.), Cytek Biosciences(U.S.), BIOMÉRIEUX (France), Q2 Solutions (a Subsidiary of IQVIA) (U.S.), Cytonome/ST, LLC (U.S.), Merck KGaA (Germany), Sony Biotechnology Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Enzo Biochem Inc. (U.S.), Takara Bio Inc. (Japan), CellKraft Biotech Pvt. Ltd. (India), IKEDA SCIENTIFIC Co., Ltd.(Japan), Apogee Flow Systems Ltd. (U.K.), Sartorius AG (Germany), Bay bioscience Co., Ltd.(Japan), Elabscience Biotechnology Inc. (U.S.), Miltenyi Biotec (Germany), CytoBuoy b.v.(Europe), ORFLO Technologies(U.S.), BioLegend, Inc. (U.S.), NeoGenomics Laboratories(U.S.), Nexcelom Bioscience LLC(U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Asia-Pacific flow cytometry market is segmented into product, technology, application, end user, and distribution channel.
- On the basis of product, the Asia-Pacific flow cytometry market is segmented into flow cytometry instruments, reagents and consumables, software, accessories, and services
- On the basis of technology, the Asia-Pacific flow cytometry market is segmented into cell-based flow cytometry and bead-based flow cytometry
- On the basis of application, the Asia-Pacific flow cytometry market is segmented into research applications, clinical applications, and industrial applications
- On the basis of end user, the Asia-Pacific flow cytometry market is segmented into academic and research institutes, hospitals, pharmaceutical and biotechnology companies, clinical testing laboratories, blood bank, and others
- On the basis of the distribution channel, the Asia-Pacific flow cytometry market is segmented into retail sales and direct tenders
Major Players
Data Bridge Market Research recognizes the following companies as the Asia-Pacific flow cytometry market players in Asia-Pacific flow cytometry market are Thermo Fisher Scientific Inc. (U.S.), BD(U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), Coherent Corp. (U.S.), Beckman Coulter, Inc. (A subsidiary of Danaher Corporation) (U.S.).
Market Developments
- In January 2022, Sony Biotechnology, Inc. launched the CGX10, a cutting-edge closed-cell isolation system designed for GMP-compliant cell sorting. This technological advancement promises new growth avenues by enhancing cost-effectiveness, accuracy, and portability. The introduction of such innovative systems addresses current demands in cell sorting applications and lays the foundation for future opportunities, showcasing Sony Biotechnology's commitment to progress in biotechnology
- In March 2022, Beckman Coulter, a subsidiary of Danaher Corp., launched CellMek SPS, a robust solution addressing data management and manual sample preparation challenges in clinical flow cytometry. This innovative system aims to streamline processes, alleviate bottlenecks, and enhance efficiency in clinical flow cytometry workflows, demonstrating Beckman Coulter's commitment to advancing technologies that optimize laboratory procedures and improve overall diagnostic capabilities
- In October 2021, BD Life Sciences collaborated with Vellore Christian Medical College to establish a Center of Excellence in flow cytometry for medical research in India. This strategic partnership aims to bolster BD's market presence by providing state-of-the-art facilities and expertise for advancing medical research. The Center of Excellence reflects BD's commitment to fostering innovation and contributing to the growth of medical research capabilities in the Indian healthcare landscape
- In July 2021, Eurofins Viracor introduced the Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing platform, utilizing flow cytometry. This innovative platform aims to assess T cell immunity against the virus, providing valuable insights for understanding immune responses. The use of flow cytometry enhances the precision and efficiency of the testing process, contributing to a comprehensive approach in evaluating immunity against SARS-CoV-2
- In January 2021, Pfizer Inc. allocated USD 120 million through the Pfizer Breakthrough Growth Initiative (PBGI) to advance biotechnology innovation. This substantial investment has fortified Pfizer's research and development infrastructure, particularly in biotechnology, biopharmaceuticals, clinical research, and life sciences. This financial commitment signifies Pfizer's dedication to fostering breakthroughs, contributing to advancements in technologies such as flow cytometry within the broader landscape of life sciences research
Regional Analysis
Geographically, the countries covered in the Asia-Pacific flow cytometry market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
As per Data Bridge Market Research analysis:
Japan is expected to dominate the Asia-Pacific flow cytometry market in the forecast period 2023-2030
Japan is expected to dominate the Asia-Pacific flow cytometry market, fueled by extensive research and development endeavors in disease diagnosis and prevention. The country's dominance is evident in market share and revenue, underscoring its robust position. With a continued focus on innovation and advancements, Japan is anticipated to sustain and further enhance its dominance in the flow cytometry market throughout the forecast period, reflecting its pivotal role in advancing healthcare and diagnostic solutions.
For more detailed information about the Asia-Pacific flow cytometry market report, click here – https://www.databridgemarketresearch.com/ar/reports/asia-pacific-flow-cytometry-market
